Schrodinger Stock Earnings Reports

Schrodinger reported a strong start to 2026 with ACV of $28.4M in Q1 (up 12% YoY) and trailing 4-quarter ACV of $201M. Total Q1 revenue was $58.6M, driven by software ($35.6M, with hosted revenue now 34% of software) and drug discovery ($22.9M). The company is accelerating its shift from on‑premise to hosted, throughput-based licensing (targeting ~75% hosted in three years), which smooths near-term recognized revenue but should create more predictable, scalable long‑term growth. Schrodinger highlighted growing customer demand, positive early adoption of its predictive toxicology solution, and the upcoming early‑access release of Bunsen — an agentic AI “co‑scientist” expected to boost throughput and broaden usage. The therapeutics business continues to validate the platform: Lilly’s announced $2.3B acquisition of Ajax (Schrodinger ~6% equity) and multiple prior exits demonstrate the commercial impact of Schrodinger‑co‑discovered molecules. Q1 operating expenses eased to $78M, net loss was $60M, and cash and marketable securities stood at $406M. Full‑year 2026 guidance was maintained: ACV $218–228M (10–15% growth) and drug discovery revenue $55–65M. The company expects to largely complete clinical activities by end of 2026, with R&D spend for clinical wind‑down of ~$10–15M for the year. Management emphasized continued investment in sales & marketing, disciplined expense management, and that any Ajax proceeds will be cash upside to the balance sheet.